A meta-analysis by Park et al reviewed 24 studies involving 3377 individuals (mean age 39.3 years, 54.8% male, mean diabetes duration 1.8 years, mean A1c 7.9%, mean body mass index (BMI) 26.4 kg/m2) to evaluate the efficacy of GLP-1 RAs (liraglutide, albiglutide, exenatide) as adjunctive therapy for T1D. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.